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As caffeine is one of the most widely consumed pharma-
cologically active compounds in the world, its possible
association with cardiovascular disease has been the subject
of scientific study for decades. Disappointingly, results
from epidemiological studies on coffee intake, the most
important dietary source of caffeine, have been equivocal.
Whereas most case–control studies have reported an
increased risk for cardiovascular disease in heavy coffee
consumers, prospective studies have in general not sup-
ported such an association [1]. Only recently have pre-
clinical studies begun to address the effect of caffeine on
therapeutic infarct size-limitation. Brief periods of ischae-
mia have been shown to limit myocardial infarct size
induced by a subsequent more prolonged ischaemic insult,
a phenomenon which has been termed ischaemic precondi-
tioning [2]. It transpired that various drugs, including the
3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) re-
ductase inhibitors (statins), can mimic the infarct size-
limiting effect of ischaemic preconditioning. Furthermore,
they confer cardioprotection when administered at the time
of myocardial reperfusion [3]. As adenosine is a pivotal
mediator of ischaemic preconditioning, we have recently
studied the effect of caffeine, which is a non-selective
adenosine receptor antagonist, in two experimental models
of preconditioning in humans, and showed that the
protective effect of ischaemic preconditioning was com-
pletely abolished by pretreatment with caffeine [4].
Although the mechanism of statin-induced cardioprotec-
tion is less extensively studied than that of ischaemic
preconditioning, there is evidence that this protection is also
dependent on adenosine receptor stimulation: in dogs,
administration of a statin immediately before coronary oc-
clusion increased activity of ecto-5′-nucleotidase, the extra-
cellular enzyme that catalyzes the conversion of adenosine
monophosphate into adenosine, and reduced infarct size,
which was abolished by pretreatment with an inhibitor of
ecto-5′-nucleotidase or the adenosine receptor antagonist
8-sulfophenyltheophylline [5]. More recently, it has been
reported that the adenosine uptake blocker dipyridamole
could potentiate atorvastatin-induced cardioprotection,
which was abolished by the adenosine receptor antagonist
aminophylline [6]. Therefore, it is logical to assume that
coffee consumption could adversely affect the cardiopro-
tective properties of statins.
In this issue of the Journal, Ye et al. have studied this
hypothesis in a rat in vivo model of myocardial infarction.
In this elegant study, they showed that a 3-day treatment
with atorvastatin reduced infarct size, which was complete-
ly abolished by concomitant administration of caffeinated
coffee, but not decaffeinated coffee, in the drinking bottle
[7]. The observation that decaffeinated coffee did not affect
atorvastatin-induced protection suggests that caffeine is the
compound responsible for the observed effects. Impor-
tantly, the plasma caffeine concentration in the caffeinated
coffee-treated group averaged 6 mg/l, which is in the same
range as the concentration reached after drinking two cups
of regular coffee [8]. Although the atorvastatin dose in this
study (10 mg/kg) was much higher than the maximum dose
given to humans (80 mg), and although a pharmacokinetic
interaction between caffeine and atorvastatin cannot be
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Given that caffeine, which is abundantly present in
significant quantities in coffee, tea, chocolate, and soft drinks,
has been shown to abolish the cardioprotective effect of
ischaemicpreconditioningandstatins,thequestionremainsas
to why previous epidemiological studies did not show a
consistent association between coffee intake and cardiovas-
cular disease? There are several possible explanations for this
apparent discrepancy. It could be that the infarct size-limiting
effects of ischaemic preconditioning and statin treatment are
not of significant importance in the general population.
However, there is some evidence that patients who have
experienced brief periods of chest pain before an acute
myocardial infarction, demonstrate a smaller infarct size [2].
In addition, there is evidence that the administration of
statins can reduce myocardial damage in patients undergoing
percutaneous coronary intervention because of chronic stable
angina or an acute myocardial infarction [9, 10].
Asthesepotentialbeneficialeffectsinvolveselectedpatient
groups, it could be that any detrimental effect of coffee intake
is not detected in large epidemiological trials in non-selected
patients. The recent finding that coffee consumption is only
associated with an increased cardiovascular risk in patients
with a CYP1A2 genotype that predicts slow caffeine
metabolism, emphasizes the possibility that coffee intake
mayhaveadverse effects incertainsubgroups ofpatients[11].
The inhibition of ischaemic preconditioning will not increase
the incidence in cardiovascular events per se, but rather
would be expected to adversely affect outcome after an acute
myocardial infarction in the subset of patients experiencing
pre-infarction angina, a group of patients which in general
have not been the subject of study in previous epidemiolog-
ical trials. Moreover, in these studies, the average daily
coffee intake is taken into account, and not the plasma
caffeine concentration at the moment of the myocardial
infarction, which is necessary to study its effect on
preconditioning- or statin-induced protection. Most prospec-
tive epidemiological trials investigating the effect of coffee
intake on cardiovascular morbidity and mortality were
started before the general introduction of statin use for the
primary and secondary prevention of cardiovascular disease
[12]. Furthermore, it should be noted that the observed
beneficial effect of atorvastatin by Ye et al. probably involves
a non-lipid lowering (“pleiotropic”) effect, although in this
study plasma lipid levels were not measured, and that coffee
is not expected to affect the beneficial consequences of its
lipid lowering effect.
Finally, there are several factors that complicate the
extrapolation of the detrimental effects of caffeine observed
in experimental studies to the clinical arena. Experimental
studies have examined the effect of acute [4] or short-term
administration of caffeine [7]. These findings do not
necessarily hold true for chronic coffee consumption,
particularly because tolerance to the cardiovascular effects
of caffeine has been described [13]. Also, it needs to be
realized that coffee contains many compounds, other then
caffeine, such as diterpene alcohols and chlorogenic acid,
which can also modulate cardiovascular risk by affecting
plasma cholesterol and homocysteine levels [1]. Recently,
coffee consumption has been associated with a lower risk of
type 2 diabetes mellitus [14] ,a n dw i t ha ni n c r e a s e d
circulating concentration of adiponectin, which has potent
cardioprotective properties [15]. In epidemiological studies,
these long-term beneficial effects of coffee intake may have
balanced its potential deleterious effects, observed in the
experimental models.
In conclusion, the association between chronic coffee
consumption and cardiovascular disease is still controversial.
Therefore,itisstilltooearlytobancoffeeasa measure oflife-
style modification in patients with cardiovascular disease.
However, the findings from the study by Ye et al. demon-
strating that coffee intake can blunt statin-induced cardiopro-
tection [7], provides yet another experimental basis to study
the acute effects of caffeine (i.e. the plasma caffeine
concentration at the moment of ischaemia) on the outcome
after a cardiac ischaemic event in selected patients with pre-
infarction ischaemia or in patients treated with statins.
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